Европска Унија - Словачки - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vakcíny - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Европска Унија - Словачки - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vakcíny - active immunisation against h5 subtype of influenza a virus.

Европска Унија - Словачки - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vakcíny - profylaxia chrípky spôsobená vírusom a (h1n1) v roku 2009. celvapan by mali byť použité v súlade s oficiálne usmernenie.

Европска Унија - Словачки - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunologické lieky, inaktivované vírusové vakcíny pre ošípané, vírus ošípaných - ošípané - aktívna imunizácia ošípaných vo veku od 8 týždňov proti pandemickému vírusu chrípky ošípaných h1n1 na zníženie zaťaženia vírusu pľúc a vírusovej exkrécie. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Европска Унија - Словачки - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - ošípané - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Европска Унија - Словачки - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - chrípkové vakcíny - profylaxia chrípky spôsobená vírusom a (h1n1v) 2009. focetria by mali byť použité v súlade s oficiálne usmernenie.

Европска Унија - Словачки - EMA (European Medicines Agency)

laboratorios syva, s.a.u. - inaktivované vírus katarálnej horúčky oviec, sérotyp 1, kmeň alg2006/01 e1, inaktivované vírus katarálnej horúčky oviec, sérotyp 4, kmeň btv-4/spa-1/2004, inaktivované vírus katarálnej horúčky oviec, sérotyp 8, kmeň bel2006/01 - inaktivované vírusové vakcíny - cattle; sheep - pre aktívnej imunizácie oviec, aby sa zabránilo virému a zníženie klinických príznakov a lézie spôsobené sérotypom sérotypy 1 a/alebo 8 a/alebo znížiť virému* a klinické príznaky a lézie spôsobené sérotypom sérotyp 4for aktívnej imunizácie dobytka, aby sa zabránilo virému spôsobené sérotypom sérotypy 1 a/alebo 8 a/alebo znížiť virému* spôsobené sérotypom sérotyp 4.

Европска Унија - Словачки - EMA (European Medicines Agency)

intervet international bv - inaktivovaného chimérneho kmeňa flavivírusov yf-wn - imunologické - kone - aktívnej imunizácie koní proti west nile virus (wnv) na zníženie klinických príznakov ochorenia a lézie v mozgu a na zníženie virému. nástup imunity: 2 týždne po primárnej vakcinácii dvoch injekcií. trvanie imunity: 12 mesiacov.

Европска Унија - Словачки - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vakcíny - hexyon (dtap-ipv-hb-hib) je indikovaná na základné očkovanie a preočkovanie dojčiat a batoliat od šesť týždňov veku proti záškrtu, hepatitíde b, detskej obrne, tetanu invazívnych ochorení spôsobených haemophilus influenzae typ b (hib). použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Европска Унија - Словачки - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vakcíny - infanrix hexa je určený na základné očkovanie a preočkovanie detí proti záškrtu, hepatitíde b, detskej obrne, tetanu ochorenie spôsobené haemophilus influenzae typu b.